Join the Riabni group to help and get support from people like you.
Riabni News
Dozens of COVID Virus Mutations Arose in Man With Longest Known Case
FRIDAY, April 19, 2024 – An immune-compromised man with a year-and-a-half-long COVID infection served as a breeding ground for dozens of coronavirus mutations, a new study discovered. Worse, several...
Updated FDA Labeling Recommendations for Biosimilar and Interchangeable Biosimilar Products
October 26, 2023 – Over the last eight years, FDA has approved more than 40 biosimilar products (biosimilars), and they have become an important treatment option for health care professionals and...
FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan (rituximab), for Adults with Moderate to Severe Rheumatoid Arthritis
THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Riabni (rituximab-arrx), a biosimilar to...
FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan
THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Riabni (rituximab-arrx), a biosimilar to...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Non-Hodgkin's Lymphoma, Rheumatoid Arthritis